Express Scripts will make an AbbVie drug the exclusive option for patients with the most common form of hepatitis C. The move will help the drug maker take market share from Gilead, maker of Sovaldi.
WSJ.com: Europe Home, Wall Street Journal: World: Home Europe
Sun, 12/21/2014 - 10:01pm
Express Scripts will make an AbbVie drug the exclusive option for patients with the most common form of hepatitis C. The move will help the drug maker take market share from Gilead, maker of Sovaldi.